Development of a sublingualoral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study

Clinical Drug Investigation

Volumn 29, Issue 5, 2009, Pages 317-324

  Chong, Chui ^a   Schug, Stephan A ^a,b,d   Page Sharp, Madhu ^b   Jenkins, Barry ^a   Ilett, Kenneth F ^b,c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; NORKETAMINE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MANUFACTURE; DRUG METABOLISM; DRUG STABILITY; DRUG STORAGE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL PHARMACY; HUMAN; LOZENGE; MALE; NEUROPATHIC PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AREA UNDER THE CURVE; BIOAVAILABILITY; CHRONIC DISEASE; COMPARATIVE STUDY; MIDDLE AGED; NEURALGIA; ORAL DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TEMPERATURE;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ADULT; AGED; ANALGESICS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHRONIC DISEASE; CROSS-OVER STUDIES; DRUG STABILITY; DRUG STORAGE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; NEURALGIA; TEMPERATURE;

EID: 65249096630     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200929050-00004     Document Type: Article

References (25)

1. Reich DL, Silvay G. Ketamine: an update on the 1st 25 years of clinical experience. Can J Anaesth 1989; 36: 186-97
2. Walker SM, Cousins MJ. Reduction in hyperalgesia and intrathecal morphine requirements by low-dose ketamine infusion. J Pain Symptom Manage 1997; 14: 129-33
3. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003; 97: 1730-9
4. Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage 2000; 19: S21-5
5. Price DD, Mayer DJ, Mao J, et al. NMDA-receptor antagonists and opioid receptor interactions as related to analgesia and tolerance. J Pain Symptom Manage 2000; 19: S7-11
6. Sator-Katzenschlager S, Deusch E, Maier P, et al. The long-term antinociceptive effect of intrathecal S(+)-ketamine in a patient with established morphine tolerance. Anesth Analg 2001; 93: 1032-4
7. Eilers H, Philip LA, Bickler PE, et al. The reversal of fentanyl-induced tolerance by administration of "small-dose" ketamine. Anesth Analg 2001; 93: 213-4
8. Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004; 99: 482-95
9. Clements JA, Nimmo WS, Grant IS. Bioavailability, phar-macokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 1982; 71: 539-42
10. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30: 853-8
11. Kannan TR, Saxena A, Bhatnagar S, et al. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002; 23: 60-5
12. Fitzgibbon EJ, Hall P, Schroder C, et al. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes: a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage 2002; 23: 165-70
13. Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine. J Pain Symptom Manage 1999; 17: 384-6
14. Gross AS, Nicolay A, Eschalier A. Simultaneous analysis of ketamine and bupivacaine in plasma by high-performance liquid chromatography. J Chromatog B 1999; 728: 107-15
15. Hijazi Y, Bolon M, Boulieu R. Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples. Clin Chem 2001; 47: 1713-5
16. Thomann P. Non-compartmental analysis methods manual. In: Heinzel G, Woloszcak R, Thomann P, editors. TopFit 2.0 pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer, 1993: 5-66
17. Heinzel G, Tanswell P. Compartmental analysis methods manual. In: Heinzel G, Woloszcak R, Thomann P, editors. Topfit 2.0 pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer, 1993: 5-140
18. Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos 2003; 24: 37-43
19. Hijazi Y, Bodonian C, Salord F, et al. Pharmacokinetic-pharmacodynamic modelling of ketamine in six neuro-traumatised intensive care patients. Clin Drug Invest 2003; 23: 605-9
20. Yanagihara Y, Ohtani M, Matsumoto M, et al. Preparation of ketamine tablets for treatment of patients with neuropathic pain. Yakugaku Zasshi 1999; 119: 980-7
21. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 1981; 53: 805-10
22. Ebert B, Mikkelsen S, Thorkildsen C, et al. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997; 333: 99-104
23. Shimoyama M, Shimoyama N, Gorman AL, et al. Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 1999; 81: 85-93
24. Edwards SR, Mather LE. Tissue uptake of ketamine and norketamine enantiomers in the rat: indirect evidence for extrahepatic metabolic inversion. Life Sci 2001; 69: 2051-66
25. Bushnell TG, Craig J. Response of chronic neuropathic pain syndromes to ketamine: a role for norketamine [letter]? Pain 1995; 60: 115